QTP101 is a tuberculosis vaccine for adolescents and adults. It is a Boosting vaccine that improves immunity for BCG vaccination. 

QTP101 consists of ID93, a subunit antigen containing 3 virulent and 1 latent antigen, and GLA-SE,  a synthetic adjuvant that maximizes stability. QTP101 is recently filied Phase 2b/3 clinical trial for global clinical trial study.

Tuberculosis or TB, is one of the world’s deadliest infectious diseases. 

It generally affects the lungs and is an airborne disease that is spread when patients cough, spit, speak or sneeze. 

Thanks to antibiotics the incidence rate of TB has significantly decreased but is on the rise again due to the emergence of HIV and antibiotic-resistant bacteria. 

The prevention effect decreases sharply after 10 years of inoculation of existing BCG vaccine, increasing the number of patients. 

In addition, tuberculosis treatments have a secondary risk of being worsened by multidrug-resistant tuberculosis due to side effects and inconvenience of medication.